Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
logo icon CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
News information

Proteomics Technique Identifies Two New Drug Targets for Treating Atherosclerosis

2016-11-02
|
Page View:

    Scientists at Brigham and Women’s Hospital say they have found two new potential drug targets for treating arterial diseases such as atherosclerosis. By using proteomics to screen a vast number of molecules, the researchers identified PARP9 and PARP14, two members of the poly(ADP-ribose) polymerase (PARP) family of proteins, as regulators of macrophage activation, which has been linked to arterial disease by systems biology studies.

 


 

    Their paper (“PARP9 and PARP14 Cross-Regulate Macrophage Activation via STAT1 ADP-Ribosylation”) is published in Nature Communications.

 

    Though the mechanisms that activate macrophages remain incompletely understood, previous research shows that macrophages play an important role in the development of atherosclerosis and its thrombotic complications. Masanori Aikawa, M.D., Ph.D., director of the Center for Interdisciplinary Cardiovascular Sciences (CICS) at the Brigham, his research fellow Hiroshi Iwata, M.D., Ph.D., and colleagues studied atherosclerosis at the protein level to determine which molecules were most involved in the regulation of macrophages.

 

    Once Dr. Aikawa and his colleagues narrowed down their search to these two proteins, they silenced each gene in cultured macrophages and found that tamping down PARP14 increased macrophage activation while tamping down PARP9 had the opposite effect.

 

    Dr. Aikawa and CICS are using a more systematic approach to drug development that hinges on network analysis, a method that predicts which pathways are most likely to control their studied effect so that they can prioritize these pathways. Ideally, this process would take a fraction of the time in comparison to searching through each individual pathway unaware of its likelihood of affecting the studied effect.

 

    Dr. Aikawa and his colleagues plan to augment these findings to develop targeted therapeutics for atherosclerosis and other diseases.

 

    “Macrophage activation plays a role in not only vascular disorders but also various inflammatory and autoimmune diseases,” said Dr. Aikawa. “These results could provide important information about the mechanisms of these diseases and help to develop much needed new therapeutics.”

Relevant newsRelevant news